Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Kurz, H; Eber, E; Frischer, T; Götz, M; Horak, E; Riedler, J; Schmitzberger, R; Zach, M; Arbeitsgruppe Pneumologie und Allergologie der Osterreichischen Gesellschaft für Kinder- und Jugendheilkunde (OGKJ); Arbeitsgruppe Pädiatrische Pneumologie und Allergologie der Osterreichischen Gesellschaft für Pneumologie (OGP).
Long-acting beta-2 agonists in pediatric asthma therapy--friend or foe
Wien Klin Wochenschr. 2006; 118(11-12):362-364
Doi: 10.1007/s00508-006-0607-0
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Eber Ernst
- Zach Maximilian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Recent publications suggest that long-acting beta-2 agonists (LABAs) increase the risk for death in asthma. The American Food and Drug Administration (FDA) published a relevant alert in 2005. In the currently valid Austrian consensus guidelines for drug therapy of bronchial asthma in children and adolescents, LABAs are only recommended as add-on therapy in those patients whose asthma is not sufficiently controlled by inhaled corticosteroids (ICS) alone. LABAs have no established role in earlier steps of the therapeutic algorithm; consequently, the prescription of ICS-LABA combinations for initial treatment of paediatric asthma is not supported by these consensus treatment guidelines.
- Find related publications in this database (using NLM MeSH Indexing)
- Adrenergic beta-Agonists - adverse effects
- Anti-Asthmatic Agents - adverse effects
- Asthma - drug therapy
- Austria - drug therapy
- Delayed-Action Preparations - drug therapy
- Practice Guidelines as Topic - drug therapy
- Risk Assessment - methods
- Risk Factors - methods